IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

Biomarkers for Alzheimer's Disease: Early Diagnosis

Biomarkers for Alzheimer's Disease: Early Diagnosis
View Sample PDF
Author(s): Deepak Panwar (Max Super Speciality Hospital, Vaishali, India), Parul Sharma (Delhi Pharmaceutical Sciences and Research University, New Delhi, India), Shweta Sharma (MM Institute of Physiotherapy and Rehabilitation, Maharishi Markandeshwar (Deemed), India), Manoj Malik (Guru Jambheshwar University of Science and Technology, Hissar, India)and Jaspreet Kaur (Guru Jambheshwar University of Science and Technology, Hissar, India)
Copyright: 2025
Pages: 44
Source title: Deep Generative Models for Integrative Analysis of Alzheimer's Biomarkers
Source Author(s)/Editor(s): Abhishek Kumar (Chandigarh University, India), S. Rakesh Kumar (GITAM University (Deemed), India), N. Gayathri (GITAM University (Deemed), India), R. Srivel (Adhiparasakthi Engineering College, India)and Dhaya C. (Adhiparasakthi Engineering College, India)
DOI: 10.4018/979-8-3693-6442-0.ch003

Purchase

View Biomarkers for Alzheimer's Disease: Early Diagnosis on the publisher's website for pricing and purchasing information.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory impairment. As the most common form of dementia, AD affects millions of individuals worldwide and poses significant challenges for diagnosis and management. Early and accurate detection of AD is critical for effective intervention and management, which has led to increasing interest in identifying and utilizing biomarkers. Biomarkers for AD include neuroimaging findings, cerebrospinal fluid (CSF) proteins, and blood-based markers. Neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) are instrumental in visualizing structural and functional changes in the brain associated with AD. CSF biomarkers, including amyloid-beta (Aβ) plaques and tau proteins, provide valuable insights into the pathological processes underlying the disease. Recent advancements in blood-based biomarkers offer promising non-invasive alternatives for early detection.

Related Content

Kavita Kanwar, Nikhil Kumar Goyal. © 2026. 30 pages.
Deepak Gupta, Raghu Nangunuri, Srinivasan Nagaraj, S. Keerthi, Pratish Rawat, C. Umarani, Someshwar Siddi. © 2026. 30 pages.
Arun Agrawal. © 2026. 22 pages.
Aditya Ojha, Sneha Singh, Jyoti Singh Kirar. © 2026. 50 pages.
Prachi Sharma Biswas, Swati Dubey Mishra. © 2026. 34 pages.
Tamara Phillips Fudge. © 2026. 34 pages.
Bayram Cadıl, Gurkan Tuna. © 2026. 34 pages.
Body Bottom